You are here

Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42GM116622-02
Agency Tracking Number: R42GM116622
Amount: $993,957.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 400
Solicitation Number: PA16-303
Timeline
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-09-01
Award End Date (Contract End Date): 2019-08-31
Small Business Information
2450 EJ CHAPMAN DR
Knoxville, TN 37996-0001
United States
DUNS: 968832498
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAN MORRISON
 (865) 604-7713
 dan.morrison@490biotech.com
Business Contact
 STEVEN RIPP
Phone: (865) 974-9605
Email: steven.ripp@490biotech.com
Research Institution
 UNIVERSITY OF TENNESSEE KNOXVILLE
 
1534 WHITE AVENUE
KNOXVILLE, TN 37916
United States

 Nonprofit College or University
Abstract

Expressing humanized bacterial luciferase in stem cellsMoving beyond firefly luciferase toexpand the informational capacity of animal models for regenerative medicine
Project Summary
This Small Business Technology TransferSTTRPhase II project proposes to develop complementary
autonomously bioluminescentautobioluminescentin vitro stem cell lines and in vivo small animal model
systems that enable the continuousreagent freeand real time bioimaging of mesenchymal stem cellMSClocalizationdifferentiation into adipocytechondrocyteand osteocyte lineagesand persistence postdifferentiation at the site of activationThese models will specifically address the National Institutes of Health s
request for new techniques for non invasivelong term tracking of stem cell survivabilityengraftmentand
migration following in vivo implantationBy addressing this critical need for new methods capable of elucidating
the mechanisms underlying how stem cells identify areas of dysfunction within the bodydifferentiate into the
relevant tissues required to correct the maladyand persist in synergy with existing tissue to enable long term
functionalitythese tools will significantly improve the transition of regenerative medicine studies towards
translational and clinical practice outcomesThe autobioluminescent MSCs developed byBioTech under
our Phase I effort demonstrated the ability to track MSC localization in vitro and in vivo similarly to existing
optical imaging approachesbut with significantly reduced cost and personnel effortFurthermorethese models
also negated the need for sample destruction or the stressful and potentially influential injection of an activating
chemical concurrent with imaging while simultaneously providing an uninterrupted stream of visual data over
the lifetime of the reporter cell as it interacts with its environment and undergoes differentiationIn partnership
with the University of Tennessee Medical Centerthis proposal will expand upon these accomplishments to
develop fully self contained autobioluminescent MSC based cellular models capable of specifically reporting on
their differentiation into adipocytechondrocyteand osteocyte lineagesand complementary small animal
models harboring native MSCs genetically programmed to autonomously enact their reporter functionality only
following differentiation into adipocytechondrocyteor osteocyte lineages in response to wounding or
exogenous stimulationThese models will overcome the primary technical hurdles encountered with all existing
bioluminescent and fluorescent stem cells currently on the market from companies such as PerkinElmerThermoFisher Life TechnologiesPromegaandsmaller specialized business entities in the U Salonewhich comprise an estimated market value of at least $ Bwith a predicated annual growth rate ofWe
believe that the products developed in this effort will be capable of significantly improving the throughput and
effectiveness of regenerative medicine studies and advancing our understanding of stem cell based treatment
efficiency and efficacy to improve both public health and consumer safetyThe functional demonstrations and
data gathered in this effort will position these models to thrive within this market and produce an immediate
and significant impact on the field of regenerative medicine that will benefit the population at large

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government